Press release
Refractory Multiple Myeloma Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Refractory Multiple Myeloma Pipeline Report to explore emerging therapies, key Refractory Multiple Myeloma Companies, and future Refractory Multiple Myeloma treatment landscapes @ Refractory Multiple Myeloma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Refractory Multiple Myeloma Pipeline Report
* In April 2025, Ontario Clinical Oncology Group announced a phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
* DelveInsight's Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Refractory Multiple Myeloma treatment.
* The leading Refractory Multiple Myeloma Companies such as MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
* Promising Refractory Multiple Myeloma Pipleline Therapies such as Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Selinexor, Bortezomib, Elranatamab,Carfilzomib, REGN5459 and others.
Stay ahead with the most recent pipeline outlook for Refractory Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Refractory Multiple Myeloma Treatment Drugs [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Refractory Multiple Myeloma Emerging Drugs Profile
* Felzartamab: MorphoSys
Felzartamab is an investigational human monoclonal antibody developed using MorphoSys' HuCAL Registered antibody technology. The antibody targets against CD38 present on the surface of multiple myeloma cells. The drug candidate uses antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) for tumor cell killing. Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma.
* RAPA-201: Rapa Therapeutics
RAPA-201 It is a type of autologous cell therapy. The drug candidate is gene transference, T lymphocyte replacements and work on the same mechanism of action. Currently the drug is being evaluated in Phase II for the treatment of Refractory Multiple Myeloma.
* PHE885: Novartis
PHE885 is an autologous, fully human, BCMA-directed CAR T-cell therapy being developed by Novartis for the treatment of refractory multiple myeloma. It is administered through intravenous route. The therapeutic candidate consists of autologous T cells that are genetically modified to express chimeric antigen receptor that targets BCMA (B-cell maturation antigen). Currently it is in Phase II stage of clinical trials.
* ABBV 453: AbbVie
ABBV-453 is an investigational drug candidate being developed for the treatment of relapsed or refractory multiple myeloma. It is administered through oral route as tablet formulation. It acts by targeting B-cell lymphoma 2 (BCL-2) protein. Currently the drug is in Phase I stage of clinical trials.
The Refractory Multiple Myeloma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Multiple Myeloma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Multiple Myeloma treatment.
* Refractory Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Refractory Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Multiple Myeloma market.
Explore groundbreaking therapies and clinical trials in the Refractory Multiple Myeloma Pipeline. Access DelveInsight's detailed report now! @ New Refractory Multiple Myeloma Drugs [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Refractory Multiple Myeloma Companies
MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Refractory Multiple Myeloma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Refractory Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Refractory Multiple Myeloma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Refractory Multiple Myeloma Pipeline Report
* Coverage- Global
* Refractory Multiple Myeloma Companies- MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
* Refractory Multiple Myeloma Pipleline Therapies- Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Selinexor, Bortezomib, Elranatamab,Carfilzomib, REGN5459 and others.
* Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Refractory Multiple Myeloma Drug development? Find out in DelveInsight's exclusive Refractory Multiple Myeloma Pipeline Report-access it now! @ Refractory Multiple Myeloma Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Multiple Myeloma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* Felzartamab: MorphoSys
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* RAPA-201: Rapa Therapeutics
* Early Stage Products (Phase I )
* Comparative Analysis
* ABBV 453: AbbVie
* Inactive Products
* Refractory Multiple Myeloma Key Companies
* Refractory Multiple Myeloma Key Products
* Refractory Multiple Myeloma- Unmet Needs
* Refractory Multiple Myeloma- Market Drivers and Barriers
* Refractory Multiple Myeloma- Future Perspectives and Conclusion
* Refractory Multiple Myeloma Analyst Views
* Refractory Multiple Myeloma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=refractory-multiple-myeloma-pipeline-appears-robust-with-75-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/refractory-multiple-myeloma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Refractory Multiple Myeloma Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4006768 • Views: …
More Releases from ABNewswire
Secure Z100 Jingle Ball MSG Seats Fast with Promo Code CITY10: Dec 12, 2025 at C …
Grab your Z100 Jingle Ball tickets at Madison Square Garden for Dec 12, 2025, fast with CapitalCityTickets.com! Use promo code CITY10 to save instantly. Don't miss performances from top artists, festive vibes, and unforgettable holiday music. Secure the best seats online today and enjoy an epic night of live entertainment at one of New York City's most iconic venues.
The Z100 Jingle Ball is back, lighting up Madison Square Garden (MSG)…
Cheapest Knicks Tickets Basketball Tickets Online - Best Prices Available with P …
Get your New York Knicks tickets online at CapitalCityTickets.com and score the cheapest prices with promo code CITY10. Whether you want courtside action or upper-level seats at Madison Square Garden, fans can enjoy NBA games without overspending. Don't miss live basketball excitement featuring Julius Randle, RJ Barrett, and the Knicks - buy your tickets today for every home game this season.
The 2025-26 NBA season is here, and New York Knicks…
Fiber Optic Cable Market Expected to Reach USD 20.94 Billion by 2030, Driven by …
Mordor Intelligence has published a new report on the Fiber Optic Cable Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Fiber Optic Cable Market Overview
The Fiber Optic Cable Market size is estimated at USD 13.92 billion in 2025, and is expected to reach USD 20.94 billion by 2030, at a CAGR of 10.46% during the forecast period (2025-2030). The market reflects increasing demand for high-speed internet, 5G…
Upgraded Systems Made Possible with Water Heater Installation in Wilmington
By ensuring reliable systems are available in homes and businesses, Powell's Plumbing & Air has become a trusted resource for essential upgrades and high-quality service.
In Wilmington, NC, demand for modern solutions such as water heater installation near me [https://www.google.com/search?water+heater+installation+near+me&kgmid=/g/1tfqb2fb] continues to grow as property owners look for ways to improve comfort and efficiency. By ensuring reliable systems are available in homes and businesses, Powell's Plumbing & Air has become a…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…
